Hints and tips:
Related Special Reports
Related Topics
...Other investors in the company are Sanofi Ventures and the Cambridge university’s venture fund....
...Sanofi’s operating income fell 5.2 per cent at the end of last year as adverse currency rates and generic competition with multiple sclerosis pill Aubagio hit sales....
...The drug is marketed by Sanofi as Lyxumia in the EU and Adlyxin in the US, where it was discontinued last year because of low demand....
...Sanofi chief executive Paul Hudson began in sales jobs at groups including GSK....
...The business accounts for just over a tenth of Sanofi’s total sales....
...His biggest challenge is convincing investors about Sanofi’s ability to deliver on development objectives....
...Last month, French group Sanofi decided to settle 4,000 claims in cases outside Delaware....
...Dupixent, which is used to treat asthma and eczema, is Sanofi’s best-selling product....
...Sanofi has since restructured the consumer division to be a standalone business within the company....
...For some pharma groups, notably Sanofi of France, the pandemic was a time of embarrassing and very public underperformance....
...Sanofi raised its full year earnings guidance after sales of its immunology drug Dupixent soared by more than a third in the second quarter....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...Germany’s Bayer and French giant Sanofi, which makes polio vaccines, have followed suit....
...Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the UK’s AstraZeneca, German software company SAP and French healthcare firm Sanofi...
...But on Tuesday night, the company announced it had failed to reduce relapse rates for MS patients compared with teriflunomide, which is produced by rival Sanofi....
...Earnings: Oil major Shell, beverage maker AG Barr and air carrier Icelandair will report, as will casino operator Rank Group and biopharma companies Novozymes, Roche and Sanofi....
...Big share price moves in Europe today include French drug company Sanofi, French video game maker Ubisoft and Dutch lighting company Signify: Sanofi: Shares in the French drugmaker dropped more than 15...
...AstraZeneca already has expertise in RSV, as the drugmaker, in partnership with Sanofi, sells an antibody that protects infants from the disease....
...Sanofi needs to show how it will replace it in order to close its valuation gap....
...Barclays analyst Emily Field believes Anderson must “at a minimum” follow the example of Sanofi, which in October named an earliest date by which it intended to carve out its own consumer healthcare business...
...The Darmstadt-based company said on Tuesday night that its drug called evobrutinib had failed to reduce relapse rates for patients compared to teriflunomide — an ingredient in rival drugmaker Sanofi’s Aubagio...
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...The next skin disorder to generate blockbusters was atopic dermatitis, led by Dupixent, developed by Regeneron and Sanofi, with 2023 sales up 34 per cent to €10.7bn....
...Shares in Sanofi and Natwest tumbled 18.6 per cent and 11.5 per cent, respectively, on underwhelming earnings reports. France’s Cac 40 lost 1.3 per cent and London’s FTSE 100 fell 0.8 per cent....
...In 2019, French drugmaker Sanofi voluntarily withdrew Zantac from the market when the US Food and Drug Administration started to investigate it....
International Edition